Gland Pharma Gains USFDA Approval for Olopatadine Solution
Filing Summary
Gland Pharma Limited has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). This product is therapeutically equivalent to Pataday Once Daily Relief by Alcon Laboratories Inc. It is indicated for treating ocular itching associated with allergic conjunctivitis. Gland Pharma, established in 1978, has expanded its operations globally, focusing on injectables and ophthalmic solutions. This approval enhances its product offerings in the ophthalmic segment.
Gland Pharma Limited has announced the receipt of approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). This product is therapeutically equivalent to the reference listed drug, Pataday Once Daily Relief, 0.7%, by Alcon Laboratories Inc. The product is indicated for the treatment of ocular itching associated with allergic conjunctivitis.
The filing does not disclose specific financial terms related to the approval of Olopatadine Hydrochloride Ophthalmic Solution. The approval allows Gland Pharma to market this product in the United States, potentially expanding its revenue streams in the ophthalmic segment. The financial implications of this approval will depend on market uptake and competitive positioning within the ophthalmic solutions market.
The scope of the approval covers the manufacturing and marketing of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) in the United States. The product is designed to provide relief from ocular itching due to allergic conjunctivitis. The therapeutic equivalence to Pataday Once Daily Relief ensures that the product meets the required standards for efficacy and safety as established by the USFDA.
Gland Pharma, established in 1978, has grown from a contract manufacturer of small-volume liquid parenteral products to a significant player in the injectable-focused pharmaceutical industry. The company operates under a business-to-business model and has a presence in over 60 countries, including the United States, Europe, Canada, Australia, and India. Its product portfolio includes a wide range of injectables such as vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company is recognized for pioneering Heparin technology in India.
The timeline for the market introduction of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) will depend on Gland Pharma’s production and distribution capabilities. The approval marks a significant milestone in the company’s efforts to expand its ophthalmic product offerings in the United States market.
Gland Pharma Limited is a pharmaceutical company focused on developing, manufacturing, and marketing sterile injectables and ophthalmic solutions. The company prioritizes expanding its global footprint and enhancing its product portfolio in the pharmaceutical industry. For more information, visit www.glandpharma.com.